Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCSZ11 |
Synonyms | |
Therapy Description |
DCSZ11 is a monoclonal antibody that targets an epitope of C1QR1 (CD93) and prevents the interaction of C1Q1R and its ligand IGFBP7, potentially resulting in decreased tumor cell proliferation and increased immune cell infiltration in the tumor microenvironment (NCI Drug DIctionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCSZ11 | DCSZ-11|DCSZ 11 | DCSZ11 is a monoclonal antibody that targets an epitope of C1QR1 (CD93) and prevents the interaction of C1Q1R and its ligand IGFBP7, potentially resulting in decreased tumor cell proliferation and increased immune cell infiltration in the tumor microenvironment (NCI Drug DIctionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |